治疗湿性年龄相关性黄斑变性的抗VEGF药物研究进展

Research progress of anti-VEGF for the therapy in wet age-related macular degeneration

湿性年龄相关性黄斑变性(wet age-related macular degeneration,wet-AMD)是引起视力不可逆损伤的重要原因,目前公认的一线治疗方式为抗VEGF治疗,但有部分患者即使反复接受抗VEGF治疗,视力仍无法提高或稳定维持。为了进一步提高湿性AMD患者有效视力,衍生出了多种新的治疗方式,包括通过相同或不同的抗新生血管靶点发挥作用、联合治疗巩固提高抗VEGF的功能、改变或简化给药方式等,本文就治疗湿性AMD的抗VEGF药物研究进展做一简要综述。

Wet age-related macular degeneration is the leading cause of the severe, irreversible vision loss in individuals over the age of 65 years. Anti-VEGF therapy has been shown to play a key role in the pathogenesis of wAMD, which is the front-line therapy admittedly. lt has no clear steady curative effect for some patients even if they accepted repeating Anti-VEGF therapy. For the purpose of visual acuity improved more, a steady flow of new therapy has emerged, such as function towards the same or different targets of antiangiogenesis, consolidating the effect by combination therapy, improving or simplifying the mode of administration, etc. This paper gives a brief review of the progress of anti-VEGF for the therapy in wet age-related macular degeneration.